Summary
For pharma teams evaluating an autoinjector platform, the relevant questions go beyond device operation: how much commercial experience sits behind the platform, what injection-volume requirements can it support, and can it support commercial-scale supply? This article examines Molly through 10 years of commercial use, including its use across more than 20 approved combination products, expansion to the 2.25 mL format, and the manufacturing capabilities supporting programs at commercial scale.
Key takeaways
- Molly is used in 20+ approved combination products across nearly 30 therapeutic indications.
- Molly 2.25 supports labeled injection volumes of 2.0 mL or more for higher-dose biologic therapies.
- Vertically integrated toolmaking, equipment development, and manufacturing support commercial-scale production.
- 90 million Molly devices were delivered globally in 2025.
- Continued investment in manufacturing, final assembly, and lower-footprint development supports future demand and supply resilience.
Document details
- Format: Product profile / Article
- Publication: Parenteral Technology Supplement 2026
- Page count: 1 page
- Estimated read time: ~3 minutes
